Everest Medicines Announces Participation in Upcoming Investor Conferences
Everest Medicines Announces Participation in Upcoming Investor Conferences |
| [27-July-2026] |
SHANGHAI, July 27, 2026 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that Ian Woo, President and Chief Financial Officer, will participate in the upcoming investor conferences. Morgan Stanley Biotech Without Borders Series 2nd Annual Evercore China Biotech Summit About Everest Medicines Everest Medicines is a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative pharmaceutical products that address critical unmet medical needs for patients in global markets. The management team of Everest Medicines has deep expertise and an extensive track record both in China and with leading global pharmaceutical companies. The Company's therapeutic areas of focus include autoimmune, ophthalmology, critical care, and CKM (cardiovascular, kidney, and metabolic) diseases. Everest Medicines has developed a fully integrated commercialization platform that combines omnichannel commercial capabilities with end-to-end product lifecycle management. Leveraging its proprietary mRNA platform, the Company is advancing its existing pipeline, including mRNA in vivo CAR-T and mRNA cancer vaccines, while selectively expanding into additional high-value therapeutic areas with blockbuster potential, and accelerating its global expansion. For more information, please visit the Company's website: www.everestmedicines.com. Forward-Looking Statements
SOURCE Everest Medicines | ||
Company Codes: HongKong:1952,HongKong:1952.HK |
Crown Equity Holdings, Inc. Announces LOI with National Junior College Prep Conference Corporation












